The capital will take ASCENT and its CLARITY instrumentation through FDA clearance to first-in-human procedures in the U.S., planned for the first half of 2027.
The three organisations now share production, lab, and office spaces, and will move forward with the joint mission of making Munich a leading location for additive manufacturing in medical technology.
The funding is designed to provide greater access to STEM education for children and young people attending specialist schools due to complex health needs or long stays in hospital.
The partnership follows the opening of Bioactivx's medical-grade filament production and cleanroom print farm facility and its obtainment of HSA approval for its flagship Bioactiv Matrix product.
KLS Martin is leveraging its LCM printers, which are operating under an ISO 13485-certified quality management system, and enabling patient- and case-specific geometries.
Stentra has been cleared by the U.S. Food and Drug Administration (FDA 510(k) K232293) and is in clinical use at leading U.S. cancer centres, including a recently announced collaboration with Stanford Health Care.
Orion has been designed specifically for application within labs and clinics and is said to be capable of manufacturing soft and rigid patient-specific devices.